Discussion  by unknown
left in place, we believe the relatively short observation
period was sufficient. We also believe from this study that
the location of pulmonary vessels (which are the vessels
heard by the Doppler catheter) are difficult to predict with-
out using the Doppler catheter. There was little predictabil-
ity of vessel location in these segmental and subsegmental
airways, making use of this device vital in avoiding contact
with major vessels lying adjacent to the airway walls. As far
as the question of creating the passages in segmental or
subsegmental bronchi is concerned, we believe this has little
relevance because both segmental and subsegmental bron-
chi are equally surrounded by emphysematous lung tissue,
as can be seen on high-resolution computed tomographic
scans. Manipulation of the of the catheters was easy in the
lower lobes, whereas in the upper lobes the procedure
required some training because of the unfavorable angle of
the bronchoscope and the need to withdraw the Doppler
catheter and introduce the cautery probe while keeping the
tip of the bronchoscope stationary. All considerations about
the clinical effects of the airway bypass procedure are
beyond the purpose of this study; namely the effect of
secretions in the patency of the passages, the best way to
keep the passages steadily open, and the clinical benefit of
the procedure.
Our study proved that the airway bypass procedure is
safely feasible in normal human subjects, as well as in
patients with emphysema requiring lung transplantation.
The Doppler device used to detect pulmonary vessels is
effective, and the cautery probe enables safe creation of
airway bypasses. These clinical results support further in-
vestigation of the efficacy of the airway bypass procedure in
patients with emphysema. In particular, animal studies with
long-term follow-up are ongoing to develop the ideal stent
to keep the passages open.
References
1. Van Allen CM, Lindskog GE, Richter HT. Gaseous interchange be-
tween adjacent lung lobules. Yale J Biol Med. 1930;2:297-300.
2. Hogg JC, Macklem PT, Thurlbeck WM. The resistance of collateral
channels in excised human lungs. J Clin Invest. 1969;48:421-31.
3. Terry PB, Traystman RJ, Newball HH, Batra G, Menkes HA. Collateral
ventilation in man. N Engl J Med. 1978;298:10-5.
4. Macklem PT. Collateral ventilation [editorial]. N Engl J Med. 1978;
298:49-50.
5. Lausberg HF, Chino K, Patterson GA, Meyers BF, Toeniskoetter PD,
Cooper JD. Bronchial fenestration improves expiratory flow in emphy-
sematous human lungs. Ann Thorac Surg. 2003;75:393-8.
6. Snider G, Kleinerman J, Thurlbeck W, et al. The definition of emphy-
sema. Report of a National Heart, Lung, and Blood Institute, Division
of Lung Disease Workshop. Am Rev Respir Dis. 1985;132:182-5.
7. Cooper JD, Patterson GA, Sundaresan RS, Trulock EP, Yusen RD, Pohl
MS, et al. Results of 150 consecutive bilateral lung volume reduction
procedures in patients with severe emphysema. J Thorac Cardiovasc
Surg. 1996;112:1319-30.
8. Sciurba FC, Rogers RM, Keenan RI, Slivka WA, Gorcsan J III, Ferson
PF, et al. Improvement in pulmonary function and elastic recoil after
lung reduction surgery for diffuse emphysema. N Engl J Med. 1996;
334:1095-9.
9. Cassart M, Hamacher J, Verbandt Y, Wildermuth S, Ritscher D, Russi
EW, et al. Effects of lung volume reduction surgery for emphysema on
diaphragm dimensions and configuration. Am J Respir Crit Care Med.
2001;163:1171-5.
Discussion
Dr Scott J. Swanson (New York, NY). This well-presented
article discusses a novel concept first presented at this year’s
meeting of The Society of Thoracic Surgeons by Dr Lausberg of
Dr Cooper’s group that examines the feasibility of creating small
passages from segmental or subsegmental airways into the paren-
chyma of the lung as a treatment for emphysema using a Doppler
device for guidance and a radiofrequency catheter to create the
passage. The idea is to provide nonanatomic routes into the lung to
permit improved ventilation. At the prior presentation, this method
was used ex vivo in human patients with emphysema undergoing
transplantation and was shown to improve a surrogate forced
expiratory volume in 1 second calculation by 78%. Today’s article
is an extension of that study and was performed in vivo at the time
of either lobectomy for lung cancer or bilateral lung transplanta-
tion for emphysema. From 1 to 5 passages were created per
patient. In the 10 patients undergoing lobectomy, there was a 20%
incidence of mild bleeding, and in the 5 patients undergoing
transplantation, this was not observed. The conclusion by the
authors is that this procedure is safely feasible.
I would like to make 1 comment and ask 4 questions. It is a
privilege to discuss an article by such a renowned group that has
made many seminal contributions in advancing the treatment of
patients with emphysema.
First, did the pathologists examine the lung specimens, and, if
so, what did they see at the site of the neopassages? Was there
hemorrhage, and how big were the channels?
Second, it is widely known and my colleagues from Boston
have shown that obstruction to air flow in emphysema occurs in
the very distal airways. How many of the passages in this exper-
iment were in the segmental airways and how many were in the
subsegmental airways, and why do you surmise that this might
have an effect on the trapped ventilation that occurs much more
distally?
Third, is it true to conclude that this is safe and feasible when
the observation period after the procedure was minutes rather than
hours or days? Are there plans to carry this out in an animal model
to truly show safety before attempting this in human subjects?
Fourth, if stenting the passages is the plan to keep the channels
patent, we know that stenting larger airways and the esophagus for
benign lesions is fraught with problems from the radial traction
and occlusion from secretions. How will these issues be ad-
dressed?
Dr Rendina. At the beginning of your discussion, you men-
tioned a 20% rate of bleeding considering the 2 episodes occurring
in the 10 patients undergoing lobectomy. The denominator should,
however, be considered the 47 passages created overall and not the
10 patients undergoing lobectomy, so that this rate drops to 4.2%.
Regarding pathology, we had performed accurate pathologic stud-
ies in previous animal experiments, including more than 100
transbronchial passages, and we could demonstrate that the pas-
sages were about 1.5 mm in diameter, there was no bleeding
around the site of the passage, and there was no necrosis of the
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surrounding tissues. Therefore, we did not find it necessary to
repeat pathologic examinations in this study.
Your second question refers to the pathophysiology at the basis
of our work. The present study is focused only on safety and
feasibility, but I will try to address the question of peripheral
airway obstruction. The concept is that unless marked intrinsic
small airway disease is present, the obstruction of the peripheral
airways is due to the hyperinflation of the lung, and it presents
mostly on expiration. Within the hyperinflated lung, collateral
ventilation allows the movement of gas independently from the
anatomic airways. The passages created should bypass this ob-
struction on expiration, while leaving inspiration unmodified. The
question of creating the passages in segmental or subsegmental
bronchi has little relevance because both segmental and subseg-
mental bronchi are equally surrounded by emphysematous lung
tissue, as can be seen on high-resolution computed tomographic
scans.
Concerning safety, the crucial point of this study was to dem-
onstrate in human subjects what we had already performed in
animal studies; that is, that the detection of the vessels around the
bronchus was accurate and that transbronchial holes reaching into
the lung parenchyma could be safely made. Therefore, we consid-
ered that a short observation time was sufficient.
As far as stents are concerned, my answer can be only specu-
lative because stents were not used in this study. It might, however,
be that the presence of a foreign body might entail further risk. I
also concur with you that the secretions potentially occluding the
stent can be a problem. However, one has to consider that secre-
tions are produced by the bronchi and not by lung parenchyma.
Therefore, in principle, secretions should not affect the patency of
the stents when we use them in the future.
Dr Walter Klepetko (Vienna, Austria). I would like to ask 2
questions. First, were those patients who underwent lobectomy
emphysematous patients?
The other question is directed to the ventilation patterns mea-
sured on the respirator. I am sure you have measured them before
and after the procedure, and at least in the patients with end-stage
emphysema with the indication for transplantation, there must
have been an immediate and dramatic change. Can you give us
some results about that?
Dr Rendina. The patients undergoing lobectomy were not
severely emphysematous, with the exception of one patient. We
have the preoperative spirometric data, but the postoperative spi-
rometric data are irrelevant because the lobe in which the bypasses
were done was removed. Also, the purpose of this study was not to
demonstrate benefit. Patients undergoing transplantation, on the
contrary, were obviously severely emphysematous. In one such
patient, the free collapse was measured, and it was found to be
improved; however, that was done in only one patient.
Dr Klepetko. In the transplantations, have you observed an
immediate increase of the ventilation parameters? If you have such
a dramatic improvement as you have been demonstrating in the
experimental setting, you must have an immediate effect on the
table there and you should measure that.
Dr Rendina. Yes, I answered that. This was not the purpose of
this study, but free collapse in the last patient demonstrated im-
provement.
Dr Carlos Saldarriaga (Medellin, Colombia). Do you think
this technique is feasible for endoscopic treatment of bullous
emphysema?
Dr Rendina. The purpose of this procedure at the present time
is not the treatment of bullae. The concept at the basis of this study
is collateral ventilation and the ability to create exit pathways that
are alternative to airways collapsed during expiration by the hy-
perinflated lung compressing from the outside.
Dr Jean Deslauriers (Sainte-Foy, Quebec, Canada). Erino, I
have to congratulate you. I think you and Joel are kind of an ideal
team.
I have a couple of worries about this procedure. First, concern-
ing these stents, you have not shown the safety of the procedure.
Many patients with emphysema have pulmonary hypertension to
begin with. When you insert the stents, if you were to hit a vessel,
it would be instant death. If you were to do a pneumothorax, it
would also be instant death because these patients have no reserve.
Second, if you leave the stents in place for some days, in the
patient with true emphysema who has a lot of purulent secretions
and is receiving cortisone, you have inserted a foreign body. The
lung moves up and down and the pulmonary artery that beats. I
think you have exactly the right conditions for a catastrophic
erosion that might occur within a week or 2 or 3 weeks. I would
be really worried about putting in foreign bodies. Obviously the
stents are going to be bigger as time goes on, so that they do not
get obstructed. You said the secretions would not go in the stents,
but they will because these patients are infected. They will cough.
Some of this pus is going to go right outside the bronchi. These are
perfect conditions for abscesses and erosions.
My second comment has to do with Dr Swanson. You are
dealing with a disease that affects the periphery of the lung. It is
common knowledge that emphysema is basically in the periphery
of the lung and not in the center of the lung, yet you are putting
these stents right where the lung is the most normal. How do you
expect to treat a disease that is basically on the surface by putting
these stents in the middle of the lung?
Other than that, I think the article is wonderful, and I recognize
Joel’s innovative ideas in the field of emphysema and his crusade
to solve the problem, but I am really worried about these stents.
Dr Rendina. Thank you, Dr Deslauriers, for your comments
and questions. Most of the points that you make, however, concern
issues that have not been addressed in this study. I wish to remind
you that stents were not used, and no follow-up beyond surgical
intervention was required in this study. Nevertheless, your com-
ments are pertinent and important with regard to the overall
procedure. We share your concern about the potential danger of
stents, particularly in the face of pulmonary hypertension. We have
not observed problems related to the various stents that we have
used in our animal experiments, although we are still in the process
of developing the ideal stent. In addition, we tend to consider
pulmonary hypertension as an exclusion criterion in our forthcom-
ing clinical studies.
The occurrence of pneumothorax was also a matter of concern.
We have therefore filled the chest with saline solution after creat-
ing the holes in the bronchi, and we have noticed no air leaks from
the parenchyma. Therefore, this study confirmed that pneumotho-
rax should not be expected as a complication.
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The issue of secretions occluding the passage cannot be solved
until the procedure undergoes clinical experimentation. There are
patients with emphysema who have many secretions and others
who do not or have much less. Although we tend to believe that
secretions will not affect the patency of the passages, our intention
is to exclude patients with extensive secretions from future clinical
trials.
Last, you argue that the most destroyed areas are located at the
periphery of the lung, and yet we create the passages through the
bronchi in the most central part of the lung, which presumably is
healthier. It is questionable whether in severe homogenous em-
physema the healthier tissue is that surrounding the airway. In
addition, the anatomic basis of collateral ventilation resides in the
fact that air can move freely within the lung parenchyma, and
therefore one passage created in a given segmental or subsegmen-
tal bronchus can, in theory, drain the whole lobe. Air-dried lung
preparations confirm what can be clearly seen on any high-reso-
lution computed tomographic scan of emphysematous lungs. The
patterns of parenchymal destruction reach deep into the lung and
around the airways, and in our study we could actually see de-
stroyed lung through the passages in those patients who had
emphysema.
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